Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Show more...
FAQ
Fennec Pharmaceuticals 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Fennec Pharmaceuticals 的股票以代號 ADH 進行交易。
Fennec Pharmaceuticals 的股價在上漲嗎?▼
ADH 股票較上週上漲 +0%,本月上漲 +0%,過去一年 Fennec Pharmaceuticals 上漲 +23.83%。
Fennec Pharmaceuticals 會發放股息嗎?▼
是的,ADH 的股息每 年度 發放一次。每股最新股息為 0.03 USD。截至今日,股息殖利率(FWD)% 為 0%。
Fennec Pharmaceuticals 有多少名員工?▼
截至 April 01, 2026,公司共有 36 名員工。
Fennec Pharmaceuticals 位於哪個產業?▼
Fennec Pharmaceuticals從事於Health Care產業。
Fennec Pharmaceuticals 何時完成拆股?▼
Fennec Pharmaceuticals 最近沒有進行任何拆股。
Fennec Pharmaceuticals 的總部在哪裡?▼
Fennec Pharmaceuticals 的總部位於 CA 的 Research Triangle Park。